A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Non-small Cell Lung Cancer
Related studies linked through entity extraction aliases.
Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
- Status
- TERMINATED
- Phase
- PHASE1
Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- N/A
Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- N/A
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
- Status
- COMPLETED
- Phase
- PHASE2
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
- Status
- TERMINATED
- Phase
- PHASE3
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Daily vs. Non-Daily SBRT for NSCLC
- Status
- TERMINATED
- Phase
- NA
Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2